State of the art in the treatment of Hodgkin lymphoma. - Wikidata - awgldk - TriplyDB

State of the art in the treatment of Hodgkin lymphoma.

State of the art in the treatment of Hodgkin lymphoma.

http://www.wikidata.org/entity/Q38017914

about

The evolving role of response-adapted PET imaging in Hodgkin lymphoma Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines Advanced hodgkin lymphoma: a new era of therapy.Hodgkin disease-an ever-evolving therapy.Cardiovascular disease after cancer therapy.A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.The clinical performance evaluation of novel protein chips for eleven biomarkers detection and the diagnostic model study Reduction of myeloid-derived suppressor cells and lymphoma growth by a natural triterpenoid.Clinical outcomes and prognostic factors of empirical antifungal therapy with itraconazole in the patients with hematological malignancies: a prospective multicenter observational study in Korea.Current status of prognostication in classical Hodgkin lymphoma.An update on emerging drugs for Hodgkin lymphoma.Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives.Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.Precision therapy for lymphoma--current state and future directions.Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials.Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma.Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass.Hodgkin lymphoma: highlights from the 2012 European School of Hematology International Conference.Blood biomarkers in adults with lymph node enlargement contribute to diagnostic significance of malignancy.High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors.Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.

P2860

Q26750993-6DB922E2-C19B-4E97-A391-8C2B31768889 Q33640172-80EA5334-57E1-4565-A664-9E281142169F Q34194160-D6A867FB-5B89-422B-8BFB-4BBF4F38C6E7 Q34463426-C5CAAF5F-3944-47D6-BFC6-1FBF8597EB1B Q34604429-6F9A02F9-1BBF-47AA-BB62-45DFE057234F Q35925674-EF03734B-D654-4423-A444-6CEC1D3FA116 Q36492734-09F662A6-8EA2-4439-874D-C431934D019C Q37235341-C45F5DFF-BD61-4A94-8B88-234FBB2B5C7F Q37418841-004AB871-8F02-40E9-9D04-9D1185AA626D Q38185063-BFCBD1EE-5031-4390-AC6E-C46D91784A56 Q38205874-9F399E70-F27E-4CBA-B036-F74A7B8B9A14 Q38205880-9F7A38FD-BF61-491B-B20A-014BA60F142A Q38205923-33E3FA85-086E-478A-B5BA-3EF720F371D0 Q38241102-5D5701C8-8EBD-4B35-8C02-7214746BA7D3 Q40040274-97857C7E-D577-47A8-A3C8-4898006A7F90 Q41592435-7A9DBB02-8AE8-42F9-97A9-AF2132F7811A Q44611640-70404B99-1BF3-4095-B0BB-083F7F7EFC4D Q45825739-55C886DA-DDA0-44D2-B384-EF72B74F8788 Q47164637-A72C3537-D009-4998-9E2A-04F9A07183AF Q49578208-BE0544F3-59CA-4C8A-82E9-43DB777B0756 Q50600769-3195A59E-7814-4136-88FC-DEAD0C2CB64A

P2860

State of the art in the treatment of Hodgkin lymphoma.

http://www.wikidata.org/entity/Q38017914

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

State of the art in the treatment of Hodgkin lymphoma.

@en

type

label

State of the art in the treatment of Hodgkin lymphoma.

@en

prefLabel

State of the art in the treatment of Hodgkin lymphoma.

@en

P1433

Q38017914-1461C8FE-1CE2-433A-965A-F9D52C9AFC99

P1476

Q38017914-689F8825-CDD1-443D-9D63-97453175E232

P2093

Q38017914-2C9BAD3E-683A-4379-84A6-90D6B20DF5FE

Q38017914-6D4435FD-AD54-4688-9BA1-4B80820C38FF

Q38017914-E714E9E5-F516-4E36-B5CE-49995F097560

P2860

Q38017914-07E5D73E-6498-4791-A465-40F0152A48B3

Q38017914-0D910618-05D7-4A94-A281-811439E13DB0

Q38017914-15539371-B42A-47A4-8FE7-11A1BDEC2C4C

Q38017914-1757FF1B-6A66-4418-93B3-9CCD08E4665A

Q38017914-1880D1A8-80FF-41A2-97AC-A71E16B6E663

Q38017914-1C1D9258-57B6-4EFD-8758-57F54F42104A

Q38017914-1F8F0546-4BE5-41A0-998A-AFD970541752

Q38017914-1FD76014-0687-4D14-BDF2-2094A197789B

Q38017914-31AD8333-0749-40DF-A7AC-56C4F806292C

Q38017914-33AF9506-C845-410F-949B-CC2A950B4BC1

P304

Q38017914-066B45FD-7163-44A7-9512-DFE67D4CBF96

P31

Q38017914-4BC19CF0-24E9-43FD-B6D5-C7A4C41ED4B1

P356

Q38017914-45A63354-FC67-4907-ABEA-7450866C3A05

P407

Q38017914-79821B40-B582-4CB3-93D0-FEF793604B0D

P433

Q38017914-141F0968-ABE8-4B1D-A499-02557FDA9835

P478

Q38017914-1E698454-F485-4224-A875-1AF7F8A5D081

P577

Q38017914-F95286F5-48D8-47A4-A2E3-516821D583D2

P5875

Q38017914-A733D3D3-6E84-492B-931E-7F18432FD6C1

P698

Q38017914-E9E59D6B-CDAB-466B-BAC7-1F91726126A4

P356

NRCLINONC.2012.91

P1433

Nature Reviews Clinical Oncology

P1476

State of the art in the treatment of Hodgkin lymphoma.

@en

P2093

Andreas Engert

http://www.w3.org/2001/XMLSchema#string

Dennis A Eichenauer

http://www.w3.org/2001/XMLSchema#string

Peter Borchmann

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

Twenty years of MOPP therapy for Hodgkin's disease

Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.

P304

450-459

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRCLINONC.2012.91

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225296443

http://www.w3.org/2001/XMLSchema#string

P698

22688578

http://www.w3.org/2001/XMLSchema#string